Inflammatory joint conditions like rheumatoid arthritis involve immune system over‑activation that leads to pain, swelling, and joint damage. In this study, researchers used a collagen‑induced arthritis model in rats—a widely accepted laboratory model that mimics key aspects of human inflammatory arthritis—to explore how cannabigerol (CBG) might influence inflammation and related joint symptoms. The goal was […]
Category: CBG
Cannabigerol (CBG) Shows Neuroprotective Effects After Ischemic Brain Injury in Animal Study (pub. Aug 2025)
Stroke and other forms of cerebral ischemia occur when blood flow to the brain is temporarily reduced, depriving neurons of oxygen and nutrients and often leading to memory loss, inflammation, and long-term brain damage. In this study, researchers investigated whether cannabigerol (CBG)—a non-intoxicating cannabinoid found in hemp—could help protect the brain following transient global cerebral […]
Cannabichromene (CBC), Cannabigerol (CBG), and Related Compounds Show Early Antitumor Activity Against Glioma (pub. June 2025)
Gliomas are aggressive brain tumors with poor prognosis, and new therapeutic strategies are urgently needed. This study used a combined in silico (computer modeling) and in vitro (laboratory cell) approach to evaluate whether compounds from Cannabis sativa—including cannabichromene (CBC) and cannabigerol (CBG)—as well as related natural molecules, may inhibit the growth of malignant glioma cells. […]